期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厄洛替尼治疗晚期肺癌10例疗效观察 被引量：3

下载PDF
导出
摘要 分子靶向治疗为化疗失败的晚期肺癌患者提供了新的机会，厄洛替尼（Erlotinib，Tarceva，OSI-774）是高特异性的表皮生长因子受体酪氨酸激酶抑制剂（EGFR—TKI），通过抑制EGFR（HER1）的磷酸化及下游信号传导、降低肿瘤与正常细胞问的黏附力而抑制肿瘤细胞增殖、侵袭、转移，促进其凋亡，延长肿瘤患者生存期。我科使用厄洛替尼治疗10例晚期肺癌患者，对服药超过4周者总结报告如下。
作者 徐文静 黄纯 李凯
机构地区 天津市肿瘤防治重点实验室、天津医科大学附属肿瘤医院肺部肿瘤内科
出处 《天津医药》 CAS 北大核心 2009年第1期65-66,共2页 Tianjin Medical Journal
关键词 肺肿瘤 癌 受体 表皮生长因子 受体蛋白质酪氨酸激酶类 蛋白酶抑制药 厄洛替尼
分类号 R734.2 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献5

  • 1Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [J].N Engl J Med, 2005,353 (2): 123-132.
  • 2Fishback NF,Travis WD,Moran CA,et al.Pleomorphic (spindle/giant cell) carcinoma of the lung.A clinicopathologic correlation of 78 cases[J].Cancer,1994,73(12):2936-2945.
  • 3Perez-Soler R.Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome [J]? Oncology (Huntingt), 2003,17 (Suppl 12):23-28.
  • 4Sequist LV,Joshi VA,Janne PA,et al.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing[J].Oncologist, 2007,12(1):90-98.
  • 5Gamou S,Shimosato Y,Merlino GT, et al. Methylation status of epidermal growth factor receptor gene in lung carcinoma cells [J].Jpn J Cancer Res,1988,79(9):989-995.

同被引文献37

  • 1Parkin DM, Bray F, FerlayJ, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer morality in China: 1991-2005. BrJ Cancer, 2004, 90(11): 2157-2166.
  • 3Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25 (Snppl 1): 3-10.
  • 4American Cancer Society. Cancer facts and figures 2005. Available at: http://www.cancer.org/docroot/STT/stt_O.asp. Accessed October 20th 2006.
  • 5Smith J. Erlotinib: Small molecule targeted therapy in the treatment of nonsmall-cell lung cancer. Clinical Therapeutics, 2005, 27(10): 1513-1534.
  • 6Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004, 64(24): 8919-8923.
  • 7Cohen MH,'Johnson JK, Chen YF, et al FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist, 2005, 10(7): 461.
  • 8Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ, 2001, 323 (7303):42-46.
  • 9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, a al. Erlotinib in previously treated non-small-celllung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 10Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small- cell lung cancer and a performance status of2.J Clin Oncol, 2008, 26(6):.

引证文献3

二级引证文献17

天津医药
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部